DongKook Pharmaceutical acquired a 53.66% stake in reBom Cosmetics for 30.66 billion won ($22.39 million).WHO: Established in 2010, reBom Cosmetics is a manufacturer specializing in cosmetics R&D and export. It has over 150 Korean clients and 34 overseas partners in 26 countries.  It has been recognized for its production quality, receiving CGMP (Current Good Manufacturing Practice) approval in 2016, ISO22716 (Cosmetic Good Manufacturing Practice) certification in 2017, and Halal certification in 2019. DongKook Pharmaceutical, established in 1968, entered the cosmetics market in 2015 with the launch of the derma-cosmetic brand Centellian24 based on the core ingredient TECA (Titrated Extract of Centella Asiatica) leveraging DongKook’s expertise in developing plant-based raw materials over the last 50 years.WHY: The acquisition aims to secure new growth engines and diversify the DongKook Pharmaceutical business. This deal will also reduce production costs by manufacturing directly. Until now, products like Centellian24 have been produced by Kolmar, Korea.IN THEIR OWN WORDS: “In the future, we will be able to achieve synergy by combining DongKook Pharmaceutical's natural product extraction technology and herbal medicine formulation development capabilities with reBom Cosmetics'R&D and manufacturing know-how,” DongKook Pharmaceutical CEO Song Joon-ho said. “We will lead in developing competitive products and promoting the excellence of K-Beauty in Korea and worldwide.”DETAILS:DongKook Pharmaceutical acquired 96,600 shares of reBom Cosmetics for 30.66 billion won ($22.39 million), securing a 53.66% stake in the company.